Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin

doi:10.1016/S0149-2918(00)88483-0

Clinical Therapeutics

Volume 22, Issue 2, February 2000, Pages 250-264

https://doi.org/10.1016/S0149-2918(00)88483-0 Get rights and content

Abstract

Objective

The purpose of this study was to assess use of a critical pathway designed to manage community-acquired pneumonia more efficiently than its management with conventional therapy.

Methods

Economic outcomes were assessed in conjunction with a cluster-design, randomized, controlled trial. Nineteen participating Canadian hospitals were randomized to implement the critical pathway (n = 9) or conventional therapy (n = 10). The critical path-way included a clinical prediction rule to guide the admission decision, treatment with levofloxacin, and practice guidelines. Patient data on medical resource use, lost productivity, and quality of life were collected prospectively for ≥ 6 weeks after treatment. Costs were calculated from the government, health care system, and societal perspectives, with imputation of missing outpatient costs and the costs of lost productivity when necessary. Bootstrapping was used to identify 95% CIs for the total cost per patient.

Results

The analysis included all eligible patients in the critical pathway (n = 716) and conventional therapy (n = 1027) arms. There were fewer hospital admissions in the critical pathway arm than in the conventional therapy arm, both overall (46.5% vs 62.2%; P = 0.01) and in low-risk patients (33.2% vs 46.8%; P < 0.001). Compared with conventional therapy, hospitals in the critical pathway arm had 1.6 fewer bed days per patient managed (P = 0.05) and used fewer inpatient medical resources. The 2 study arms had similar outpatient, readmission, and lost-productivity costs, and similar quality-of-life outcomes. The critical pathway produced cost savings from all 3 perspectives that ranged from $457 to $994 per patient.

Conclusions

The critical pathway employing levofloxacin resulted in cost savings compared with conventional therapy and did not compromise health outcomes.

References (30)

GaribaldiRA
Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, and impact
Am J Med.
(1985)
NiedermanMS et al.
The cost of treating community-acquired pneumonia
Clin Ther.
(1998)
GilbertK et al.
Variations in antimicrobial use and cost in more than 2,000 patients with communityacquired pneumonia
Am J Med
(1998)
RhewDC et al.
The clinical benefit of in-hospital observation in “low-risk” pneumonia patients after conversion from parenteral to oral antimicrobial therapy
Chest
(1998)
MarrieTJ
Community-acquired pneumonia
Clin Infect Dis.
(1994)
BartlettJG et al.
Communityacquired pneumonia
N Engl J Med.
(1995)
MarstonBJ et al.
Preliminary findings in a communitybased pneumonia incidence study
GuestJF et al.
Community acquired pneumonia: The annual cost to the National Health Service in the UK
Eur Respir J.
(1997)
British Thoracic Society
Guidelines for the management of community acquired pneumonia in adults admitted to hospital
Br J Hosp Med.
(1993)
NiedermanMS et al.
Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
Am Rev Respir Dis.
(1993)

LaupacisA et al.

Clinical prediction rules. A review and suggested modifications of methodological standards

JAMA.

(1997)

FineMJ et al.

A prediction rule to identify low-risk patients with community-acquired pneumonia

N Engl J Med.

(1997)

WeingartenSR et al.

Evaluation of a pneumonia practice guideline in an interventional trial

Am J Respir Crit Care Med

(1996)

Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for the treatment of community acquired...

FileTM et al.

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

Antimicrob Agents Chemother

(1997)

Cited by (44)

Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions
2019, Value in Health
Citation Excerpt :
Twelve cost-effectiveness studies of other interventions targeting pneumococcal diseases, conducted in the United States (7 studies), Spain (2 studies), the Netherlands (2 studies), and Canada (1 study), were identified (see Appendix Table 5 in Supplemental Materials found at https://doi.org/10.1016/j.jval.2019.06.011). Interventions such as outreach programs to promote vaccination,200 early disease detection and treatment,201 procalcitonin protocols in CAP,202 diagnostics,203 patient management,204-207 treatment with guidelines,208 screening,209 and educational programs210,211 were found to be cost-effective. We identified a heterogenous body of evidence on health utility values in individuals with pneumococcal disease, resource use and economic costs associated with pneumococcal disease, and the cost-effectiveness of a range of intervention strategies targeting pneumococcal diseases including adult and childhood vaccines, use of antibiotics and other non-medical strategies.
Pneumococcal diseases cause substantial mortality, morbidity, and economic burden. Evidence on data inputs for economic evaluations of interventions targeting pneumococcal disease is critical.
To summarize evidence on resource use, costs, health utilities, and cost-effectiveness for pneumococcal disease and associated interventions to inform future economic analyses.
We searched MEDLINE, Embase, Web of Science, CINAHL, PsycINFO, EconLit, and Cochrane databases for peer-reviewed studies in English on pneumococcal disease that reported health utilities using direct or indirect valuation methods, resource use, costs, or cost-effectiveness of intervention programs, and summarized the evidence descriptively.
We included 383 studies: 9 reporting health utilities, 131 resource use, 160 economic costs of pneumococcal disease, 95 both resource use and costs, and 178 economic evaluations of pneumococcal intervention programs. Health state utility values ranged from 0 to 1 for both meningitis and otitis media and from 0.3 to 0.7 for both pneumonia and sepsis. Hospitalization was shortest for otitis media (range: 0.1-5 days) and longest for sepsis/septicemia (6-48). The main categories of costs reported were drugs, hospitalization, and household or employer costs. Resource use was reported in hospital length of stay and number of contacts with general practitioners. Costs and resource use significantly varied among population ages, disease conditions, and settings. Current vaccination programs for both adults and children, antibiotic use and outreach programs to promote vaccination, early disease detection, and educational programs are cost-effective in most countries.
This study has generated a comprehensive repository of health economic evidence on pneumococcal disease that can be used to inform future economic evaluations of pneumococcal disease intervention programs.
Transitional care management reimbursement to reduce COPD readmission
2014, Chest
Citation Excerpt :
To prevent this heightened surveillance from leading to an increase in readmissions, pulmonologists will need better guidance on indications for rehospitalization. Prior experience with prognostic scoring systems such as the pneumonia severity index (PSI)26 and more recently, the CURB-65 (confusion of new onset [defined as AMT ≤ 8], urea > 7 mmol/L [43 mg/dL], respiratory rate ≥ 30 breaths/min, BP < 90 mm Hg systolic or diastolic BP ≤ 60 mm Hg, age ≥ 65 y) and CRB-65 (confusion of new onset [defined as AMT ≤ 8], respiratory rate ≥ 30 breaths/min, BP < 90 mm Hg systolic or diastolic BP ≤ 60 mm Hg, age ≥ 65 y)27 have reduced the number of low-risk patients with pneumonia who are hospitalized by 18% and have saved up to $994 per patient without decreasing quality of care.28,29 For COPD, such a risk score may be best used longitudinally, to compare patient’s level of illness at the time of discharge with their acuity at the time of posthospital ambulatory care.
Reducing preventable readmissions for COPD is an important national health policy goal. Thus far, Centers for Medicare & Medicaid Services (CMS) policies focused on incentivizing improvements in inpatient quality have had variable success. In its 2013 physician-payment rule, CMS announced new payments that reimburse ambulatory care providers for timely posthospital visits and transitional care management services. CMS hopes that posthospital transitional care and services will substitute for readmission, but the evidence supporting this hypothesis is mixed. In this article, we discuss ways for ambulatory pulmonologists to leverage transitional care management payments to enhance access for their patients with COPD while minimizing the risk of a paradoxic increase in readmission rates.
Guideline adherence and macrolides reduced mortality in outpatients with pneumonia
2012, Respiratory Medicine
For outpatients with pneumonia, guidelines recommend empiric antibiotics and some suggest macrolides are preferred agents. We hypothesized that both guideline-concordant antibiotics and macrolides would be associated with reduced mortality.
All outpatients with pneumonia assessed at 7 Emergency Departments in Edmonton, Alberta, Canada were enrolled in a population-based registry that included clinical-radiographic data, Pneumonia Severity Index (PSI) and treatments. Guideline-concordant regimens included macrolides and respiratory fluoroquinolones; other regimens were “discordant”. Main outcome was 30-day all-cause mortality.
The study included 2973 outpatients; mean age 51 years, 47% female, most had mild pneumonia (73% PSI Class I–II). Over 30-days, 38 (1%) patients died, 228 (8%) were hospitalized, and 253 (9%) reached the endpoint of death or hospitalization. Most (2845 [96%]) patients received guideline-concordant antibiotics. Compared to patients receiving discordant antibiotics, those receiving guideline-concordant antibiotics were less likely to die within 30-days (8 [6%] versus 30 [1%], adjusted OR 0.23, 95% CI 0.09–0.59, p = 0.002). Within the guideline-concordant subgroup, compared to the 947 (33%) patients treated with fluoroquinolones, those receiving macrolides [1847 (64%)] were less likely to die (25 [3%] versus 4 [0.2%], adjusted OR 0.28, 95% CI 0.09–0.86, p = 0.03).
In outpatients with pneumonia, treatment with guideline-concordant antibiotics and macrolides were both associated with mortality reduction.
Severe Community-Acquired Pneumonia
2009, Infectious Disease Clinics of North America
Citation Excerpt :
Adherence to clinical practice guidelines for the treatment of CAP improves quality and efficiency of care.76 Several studies report the use of a critical pathway to improve the treatment of CAP patients, including those who have severe disease.77–82 Other publications71,83–85 have consistently found a decrease in mortality with the introduction of guideline-concordant antimicrobial therapy or guideline-based protocols.
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. It accounts for 500,000 hospitalizations and 45,000 deaths each year, and it represents one of the most common causes of ICU admission. The mortality rate due to severe CAP has shown little improvement over the past few years, with rates as high as 58% when patients were admitted to the ICU. Significant interest has focused on the sickest patients who have pneumonia treated in the ICU, regarding identification of need for ICU admission and therapies directed to improve outcomes in patients who have severe CAP. This article reviews epidemiologic, microbiologic, therapeutic, preventive, and outcomes data in patients who have CAP in the ICU.
Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia
2005, American Journal of Medicine
We assessed the performance of 3 validated prognostic rules in predicting 30-day mortality in community-acquired pneumonia: the 20 variable Pneumonia Severity Index and the easier to calculate CURB (confusion, urea nitrogen, respiratory rate, blood pressure) and CURB-65 severity scores.
We prospectively followed 3181 patients with community-acquired pneumonia from 32 hospital emergency departments (January–December 2001) and assessed mortality 30 days after initial presentation. Patients were stratified into Pneumonia Severity Index risk classes (I–V) and CURB (0–4) and CURB-65 (0–5) risk strata. We compared the discriminatory power (area under the receiver operating characteristic curve) of these rules to predict mortality and their accuracy based on sensitivity, specificity, predictive values, and likelihood ratios.
The Pneumonia Severity Index (risk classes I–III) classified a greater proportion of patients as low risk (68% [2152/3181]) than either a CURB score <1 (51% [1635/3181]) or a CURB-65 score <2 (61% [1952/3181]). Low-risk patients identified based on the Pneumonia Severity Index had a slightly lower mortality (1.4% [31/2152]) than patients classified as low-risk based on the CURB (1.7% [28/1635]) or the CURB-65 (1.7% [33/1952]). The area under the receiver operating characteristic curve was higher for the Pneumonia Severity Index (0.81) than for either the CURB (0.73) or CURB-65 (0.76) scores (P <0.001, for each pairwise comparison). At comparable cut-points, the Pneumonia Severity Index had a higher sensitivity and a somewhat higher negative predictive value for mortality than either CURB score.
The more complex Pneumonia Severity Index has a higher disciminatory power for short-term mortality, defines a greater proportion of patients at low risk, and is slightly more accurate in identifying patients at low risk than either CURB score.
Antimicrobial treatment of community-acquired pneumonia
2005, Clinics in Chest Medicine

View all citing articles on Scopus

View full text

Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin

Abstract

Objective

Methods

Results

Conclusions

Am J Med.

Clin Ther.

Am J Med

Chest

Community-acquired pneumonia

Clin Infect Dis.

Communityacquired pneumonia

N Engl J Med.

Preliminary findings in a communitybased pneumonia incidence study

Community acquired pneumonia: The annual cost to the National Health Service in the UK

Eur Respir J.

Guidelines for the management of community acquired pneumonia in adults admitted to hospital

Br J Hosp Med.

Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy

Am Rev Respir Dis.

Clinical prediction rules. A review and suggested modifications of methodological standards

JAMA.

A prediction rule to identify low-risk patients with community-acquired pneumonia

N Engl J Med.

Evaluation of a pneumonia practice guideline in an interventional trial

Am J Respir Crit Care Med

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

Antimicrob Agents Chemother